Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(♦♦ Grant Support: This study was funded by Roche. The sponsor contributed to study design as well as data collection, analysis, and interpretation with input from the investigators. Writing support was provided by Blair Jarvis of Health Interactions and funded by Hoffman La-Roche Ltd. ClinicalTrials.gov Identifier: NCT00517439)

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(♦♦ Grant Support: This study was funded by Roche. The sponsor contributed to study design as well as data collection, analysis, and interpretation with input from the investigators. Writing support was provided by Blair Jarvis of Health Interactions and funded by Hoffman La-Roche Ltd. ClinicalTrials.gov Identifier: NCT00517439)

Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (4...

Full description

Bibliographic Details
Main Authors: David R. Nelson, Stefan Zeuzem, Pietro Andreone, Peter Ferenci, Robert Herring, Donald M. Jensen, Patrick Marcellin, Paul J. Pockros, Maribel Rodríguez-Torres, Lorenzo Rossaro, Vinod K. Rustgi, Thomas Sepe, Mark Sulkowski, Isaac R. Thomason, Eric M. Yoshida, Anna Chan, George Hill
Format: Article
Language:English
Published: Elsevier 2012-01-01
Series:Annals of Hepatology
Subjects:
Chronic hepatitis C
SVR
Safety
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119314826

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119314826

Similar Items